Laguna Bio
Next generation bispecific antibody cancer therapy.
Laguna Bio is active in the healthcare space based in United States, founded in 2022.
Profile
More info at the IndieBio website We have shown in people that our technology expands and activates gamma delta T cells, up to 10,000x better than other known approaches. This profound and durable effect can be harnessed as a monotherapy, or in combination with bispecific T cell engagers (BiTEs). We are at the seed stage with human clinical data to support our approach, significant IP protection, and traction with pharma partners to generate early clinical validation with their bispecific antibodies.
Laguna Bio is positioned in healthcare, a segment that rewards a clear, focused offering.
Its base of operations is United States.
It is recorded at the SOSV portfolio company stage.
Its team size is recorded as 2-10 employees.
Public records show total funding of about $1.5M.
| Sector | Healthcare |
|---|---|
| Country | United States |
| Founded | 2022 |
| Employees | 2-10 |
| Stage | SOSV portfolio company |
| Total funding | $1,500,000 |
Website: lagunabio.com
Create a free account